<scp>DKK1</scp> drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with <scp>anti‐DKK1</scp> therapeutic <scp>DKN</scp> ‐01

Edward J. Jarman(Western General Hospital), Luke Boulter(MRC Institute of Genetics and Molecular Medicine), Stephanie MacMaster(Institute of Genetics and Cancer), David H. Wilson(University of Zimbabwe), Konstantinos Gournopanos(Institute of Genetics and Cancer), Michael H. Kagey, Panagiota Tsokkou(Institute of Genetics and Cancer), Marta Horcas‐Lopez(MRC Centre for Reproductive Health), Jeffrey W. Pollard(Albert Einstein College of Medicine), Scott H. Waddell(Edinburgh Cancer Research), William Cambridge(Institute of Genetics and Cancer), Walter Newman(Ensemble Therapeutics (United States)), Minn E Ng(Institute of Genetics and Cancer), Kamila Irena Musialik(Institute of Genetics and Cancer), Daniel Soong(MRC Centre for Reproductive Health)
Liver International
August 4, 2022
Cited by 20


Related Papers